Oncotelic Therapeutics, Inc. OTLC
Set alert
0.02 USD 0.00 0.00%
As of Nov 2, 3:51 PM ET
0.016 Day range 0.0195
0.016 52-week range 0.11
- YTD
- -79.38%
- 1 year
- -83.50%
- Open
- 0.0195
- Prev close
- 0.0165
- Mkt cap
- 7.55M
- Vol
- 325.95K
- Avg vol
- 347.37K
- EPS
- 0.59
- P/E
- 0.03
More statistics
- Low
- 0.016
- High
- 0.0195
- Earnings
- Aug 18, 2023
2Y chart
Events in this range
- Nov 19, 2024Earnings: 0; estimate 0; surprise —%
Signals (85)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 29, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 25, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 2 months ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 13, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 24, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 23, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 16, 2026 | 3 months ago |
| RSI: Oversold | Jul 13, 2026 | 3 months ago |
| SMA: Bearish | Jun 24, 2026 | 4 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
Newest 20 of 85.
Next earnings
Aug 18, 2023
Expected Aug 18, 2023. Consensus EPS estimate 0.00.
Financials — quick view
OTLC Revenue — quarterly 70.00K
OTLC Net income — quarterly 115.31K
OTLC EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 19, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | 0.00 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | 0.00 | — | — |
| Apr 12, 2024 | Dec 1, 2023 | 0.00 | 0.00 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 18, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
News
- Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature
- Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery
- PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
- Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th
- Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
- Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
- Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
- Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
- Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
- NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies
Your note
Sign in to keep a note on OTLC — it syncs with the Stock Master app.